Serious adverse events
infections
INFECTIONS
No SAEs were recorded over the AE reporting period, i.e. before departure to Benin. After this period, 17 SAEs were recorded in the active and 24 in the placebo group, all considered unrelated to the study drug. The rates of at least one SAE amongst vaccine versus placebo recipients were 16/374 (4.3%)/21/375 (5.6%); the most common SAEs were infections (3.5/4.5%). No statistically significant differences were observed in the SAE rates between vaccine and placebo recipients (Participants with SAEs


